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Abstract
Infection with the hepatitis C virus (HCV) is a major cause of chronic liver diseases and hepatocellular carcinoma worldwide,
and thus represents a significant public health problem. The type I interferon (IFN), IFNa, has been successful in treating
HCV-infected patients, but current IFN-based treatment regimens for HCV have suboptimal efficacy, and relatively little is
known about why IFN therapy eliminates the virus in some patients but not in others. Therefore, it is critical to understand
the basic mechanisms that underlie the therapeutic resistance to IFN action in HCV-infected individuals, and there is an
urgent need to identify those patients most likely to respond to IFN therapy for HCV. To characterize the response of HCV-
infected patients to treatment with IFNa, the expression of an IFN-response gene signature comprised of IFN-stimulated
genes and genes that play an important role in the innate immune response was examined in liver biopsies from HCV-
infected patients enrolled in a clinical trial. In the present study we found that the expression of a subset of IFN-response
genes was dysregulated in liver biopsy samples from nonresponsive hepatitis C patients as compared with virologic
responders. Based on these findings, a statistical model was developed to help predict the response of patients to IFN
therapy, and compared to results obtained to the IL28 mutation model, which is highly predictive of the response to IFN-
based therapy in HCV-infected patients. We found that a model incorporating gene expression data can improve
predictions of IFN responsiveness compared to IL28 mutation status alone.
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Introduction
Hepatitis C virus (HCV) is estimated to infect ,170 million
people worldwide, causing a wide spectrum of liver diseases that
varies from the asymptomatic carrier state to end-stage liver
diseases [1]. These include chronic hepatitis, cirrhosis, liver failure,
and hepatocellular carcinoma. Classified within the Flaviviridae
family of enveloped, single-stranded, positive-sense RNA viruses,
HCV has a tightly restricted host range confined to humans and
chimpanzees, and replicates predominantly in hepatocytes. For
reasons that have remained elusive, only a fraction of HCV-
infected individuals spontaneously clear the virus, while the
majority of HCV-infected individuals (70–80%) develop a chronic
infection. Several structural and nonstructural proteins of HCV
have been shown to antagonize the host innate immune response
that is normally triggered by viral infection [2]. Viral RNA is a
potent inducer of the host immune response and is recognized by
specific Toll-like receptors in endosomal compartments or by the
RNA helicases RIG-I and MDA5 in cytoplasm [3]. Rapid
induction of the interferon (IFN) system, type I IFNs (IFNa, IFNb
and IFNv, type II IFN (IFNc) and type III IFN (IL29, IL28A and
IL28B), is a central event in establishing the host innate antiviral
response that is downstream of TLR (Toll-like receptor)-depen-
dent and TLR–independent pathways [4]. IFN acts in a paracrine
and autocrine fashion to regulate gene expression that results in
the induction of an antiviral state [5]. HCV control of the innate
antiviral responses, especially at the level of IFN production, may
provide a cellular foundation for viral persistence [6].
The pegylated derivative of IFNa (peg-IFN) and the antiviral
drug ribavirin combined with a protease inhibitor is the current
standard-of-care for HCV-infected patients [7]. IFNa has antiviral
activity against a diverse variety of RNA and DNA viruses. When
IFNa has been utilized as a monotherapy in chronically infected
HCV patients, the success rate is ,20%. Peg-IFNa, which has an
improved half-life over standard IFNa, appears to have a
somewhat higher success rate. However, it is unknown why IFNa
therapy causes a sustained virological response in only a fraction of
the patient population, as determined by the clearance of HCV.
Moreover, several studies have identified specific cohorts of
patients that have a relatively low response to these therapeutic
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regimens. For example, several studies established that the
response rate of African-Americans is significantly lower than
non-Hispanic whites [8–10]. This finding is of major health
concern in the United States, since African-Americans account for
,22% of the HCV-infected patients. Recently, single nucleotide
polymorphisms within the IL28B locus, which encodes members
of the IFNl family, have been found to be highly predictive of the
response to IFN/ribavirin therapy in HCV-infected patients [11–
15]. While this represents a major advance in the field, the
underlying mechanism for differential response in HCV-infected
patients remains elusive.
To characterize the response of HCV-infected patients to
treatment with type I IFN, the expression of an IFN-response gene
signature was examined in liver biopsies. Based on microarray
analysis we previously performed on IFN-treated human and
mouse cells as well as a public database of IFN-stimulated genes
(ISGs) [16–19], ISGs were stratified into genes that are most
commonly induced by IFN and had putative binding sites with
strong DNA binding scores for STAT2 (ISRE), STAT3/STAT1
(SIE), and NF-kB. The IFN-induced expression of these ISGs in
Huh7 hepatoma cells was verified by quantitative real time PCR
as being strongly IFN-induced (.10-fold) and the ISGs were
placed into the following categories: 1) ISGs whose expression is
predominantly driven by an ISRE; 2) ISGs whose expression is
predominantly driven by an ISRE and potentially regulated by
NF-kB; 3) ISGs whose expression is predominantly driven by an
SIE; and 4) ISGs whose expression is predominantly driven by an
SIE, and potentially regulated by NF-kB. An IFN signature gene
list of 39 genes was then established based on a bioinformatic
search of these genes as potentially playing important roles in the
biological actions of IFN. The expression of this gene signature
was examined in samples of formalin-fixed paraffin embedded
(FFPE) tissue from liver biopsies obtained prior to the onset of any
therapy in patients whose clinical course and response to IFN/
ribavirin therapy was subsequently characterized in a clinical trial
at UTHSC. Our results suggest that only a subset of the IFN-
response gene signature was dysregulated in liver biopsies from
chronically infected HCV patients. Moreover, we determined the
predictive value of this gene signature and that of polymorphisms
of IL-28 locus. Our results indicate that, besides nucleotide
polymorphisms of IL-28 locus, this IFN response gene signature
has important predictive value in determining which patients will




Adult African American (AA) and Caucasian (C) patients with
compensated chronic HCV were enrolled and treated at the
UTHSC General Clinical Research Center as part of our clinical
trial entitled ‘‘Racial Differences in HCV-Host Interaction’’.
Patients were required to be adult, AA or C with genotype 1A or
1B chronic hepatitis C with positive HCV RNA and no prior
attempt at treatment. A liver biopsy was required with the
histological diagnosis of chronic hepatitis. Patients with histological
diagnosis of cirrhosis were enrolled if they did not have
symptomatic portal hypertension and if they had a neutrophil
count greater than 1500/mm3, platelet count of 85,000/mm3,
albumin level greater than 3.0 g/dL and serum creatinine less
than 1.4 mg/dL. All clinical investigation was conducted accord-
ing to the principles expressed in the Declaration of Helsinki. All
patients signed written informed consent specific for this protocol
that was approved by the UTHSC IRB before entry into the
study. Exclusion criteria included any cause of chronic liver disease
other than HCV, HIV infection, active hemolytic anemia,
evidence of decompensated cirrhosis with ascites, bleeding varices
or portosystemic encephalopathy. In addition, patients with any
known preexisting medical conditions that could interfere with
participation such as uncontrolled seizure disorders, poorly
controlled diabetes, serious pulmonary disease, immunologically-
mediated disease, gout or any medical condition likely to require
steroids during the course of the study were excluded from this
study. Patients with cardiac ischemia, significant arrhythmia,
cardiac failure, active substance abuse, retinal abnormalities,
organ transplantation, HIV infection or serious psychiatric disease
were also excluded. General clinical patient information is shown
in Table 1.
Treatment Regimen
All patients were treated with standard weight-based therapy
with 1.5 mg/kg of pegylated IFNa2b subcutaneously once per
week and 13 mg/kg of ribavirin PO daily for up to 48 weeks.
Therapy was discontinued after 24 weeks if patients did not have a
negative HCV RNA level. Use of erythropoietin was allowed.
Patients who completed at least 12 weeks of therapy were
classified as Sustained Viral Responders (SVR) if they cleared virus
on treatment and remained virus-free for 6 months after
completion of therapy. Non–responders (NR) were defined as
patients who never cleared virus. Patients who initially had a
negative HCV RNA level upon treatment but subsequently
became positive again for HCV RNA (either during continued
treatment or within 6 months after completing therapy) were
defined as Relapsers (R).
Gene expression analysis of RNA obtained from FFPE
liver biopsies
Formalin-fixed paraffin embedded (FFPE) pre-treatment liver
biopsy specimens from ,130 patients were retrieved, 3–5 (5 mm)
curls were cut from each liver biopsy and RNA isolated using the
RecoverAll Total Nucleic Acid Isolation Kit (Ambion Inc.)
according to the manufacturer’s directions. Gene expression
analysis was conducted on the nCounter Analysis System (Nano-
String Technologies) using a codeset designed to target 43 genes
(39 genes in an IFN gene signature and 4 potential house-keeping
genes: ACTB, GAPDH, GUSB, PGK1) and 15 controls (58-plex
codeset). The 39 genes in the IFN gene signature targeted in the
gene array are listed in Table 2. In brief, 100 ng of total RNA was
mixed with pairs of capture and reporter probes and hybridized on
the nCounter Prep Station. Upon removal of unbound probes, the
purified ternary complexes were bound to the imaging surface,
elongated, immobilized, and quantified on the nCounter digital
analyzer. To account for differences in hybridization and
purification, data were normalized to the average counts for all
control spikes in each sample and analyzed with nSolver software.
The expression data was normalized by using a geometric mean of
the four housekeeping genes (ACTB, GAPDH, GUSB, PGK1) in
our codeset as previously described [20]. Only two RNA samples
out of the 132 samples prepared from FFPE liver biopsies were not
used in further analysis due to low retrieved RNA levels or marked
degradation of RNA extracted from the FFPE tissue. Thus, gene
expression in 130 samples was subjected to analysis and
represented 43 hepatitis C-infected patients who responded to
IFNa-ribavirin therapy (responders), 56 hepatitis C-infected
patients who did not respond to therapy (nonresponders), and
31 patients who had an initial virological response but then
relapsed and exhibited high viral HCV titers (relapsers). FFPE
IFN Gene Signature and HepC Patient Response
PLOS ONE | www.plosone.org 2 August 2014 | Volume 9 | Issue 8 | e104202
tissue from 80 African-American and 50 Caucasian hepatitis C-
infected patients were studied in this dataset.
IL28B SNP sequence analysis
The 184 bp genomic DNA fragment that included the 19q13
rs12979860 SNP at nucleotide 92 was amplified by PCR using the
following primers: forward 59-CTGCACAGTCTGGGATTCC-
39 and reverse 59-TCACAGAAGGGAGCCCTGC-39. Nucleo-
tide sequences were generated with an ABI Model 3130XL Gene
Analyzer (Applied Biosystems, Life Technologies, Carlsbad, CA)
in the UTHSC Molecular Resource Center, and the sequence at
position 92 of the PCR fragment was determined using Sequence
Scanner v.1.0 (Applied Biosystems).
Statistical analysis and modeling
The data on expression of the IFN gene signature in the
different patient subgroups were subjected to nonparametric
Mann-Whitney analysis using Graphpad InStat 3 software, with
p-values ,0.05 considered statistically significant. We then built a
predictive model for response using logistic regression. Only full
responders were considered successfully treated, with relapsers and
non-responders considered unsuccessful. In our initial model, self-
reported race and continuous expression of each statistically
significant genes identified in univariable analysis were included as
predictors of response to interferon. We then refined our model
using a backwards selection procedure, where the model was fit
repeatedly, removing the least informative genes at each step.
Patients with a model-based probability of .0.5 were categorized
as predicted responders. We used 10-fold cross validation to test
the predictive ability of each model [21], so that our final model
demonstrated the highest agreement with true response across the
validation sets. We also considered models in the subset of patients
whose IL28B SNP data was available. Under a per-allele model,
we added IL28B status to the logistic regression models and
compared the results to expression-based models. The regression
procedures were performed using R software (version 2.13).
Results
The expression of an IFN-response gene signature in liver
biopsies
Total RNA was extracted from curls cut from FFPE liver
biopsies collected from patients prior to the initiation of therapy,
and assayed on a Nanostring nCounter for expression of an IFN
gene signature that we designed based on our own microarray
results, databases of IFN-stimulated genes (ISGs), and regulatory
elements in gene promoter regions. The expression of these genes
was then normalized to the expression of four housekeeping genes
(Actin B, GAPDH, GUSB and PGK1) that was included in the
Nanostring analysis. As shown in Table 1 there was a large
sample-to-sample variation in the expression of the genes in the
IFN signature. Some genes were expressed at low but detectable
levels such as cytokine and growth factors, including ANGPT2,
IFNB1, IL6 and VEGFC, as well as classical IFN-stimulated genes
such as Mx1, SOCS1 and TLR3. In addition a number of genes
critical in the IFN response pathway, which included GBP1,
MAVS, TNFSF10 (TRAIL), and XAF1, were expressed at
relatively high levels in liver biopsies. These results are consistent
with our previous finding that low levels of type I IFNs could be
detected in the sera of patients chronically infected with HCV
[22], as well as the findings that ISG expression could be detected
in the livers of HCV-infected patients and in experimentally-
infected chimpanzees [23–26].
Table 1. Enrolled patient information.
AA C
Patients enrolled 145 82
Male 54 38
Average age (s.d.) 48.5 (7.97) 44.3 (9.51)
Average weight1 (s.d.) 198.6 (32.91) 205.0 (39.76)
Female 91 44
Average age (s.d.) 48.9 (42.1) 46.0 (7.99)
Average weight1 (s.d.) 185.2 (41.92) 170.9 (56.18)
Il28B rs12979860 Genotype2 CC 9 (8.4%) 20 (33%)
TT 39 (36%) 6 (10%)
C/T 59 (55%) 34 (57%)
Infected with genotype 1a3 99 69
1b 45 10
Average years infected (max/min) 22 (43/1) 21 (47/3)
Average pre-therapy serum HCV IU/ml4 (s.d.) 1,064,878 (1,377,098) 1,599,894 (2,451,571)
Average ALT (s.d.) 88 (62) 103 (65)
Average fibrosis score (s.d.)5 2.0 (1.1) 1.9 (0.9)
Mild fibrosis (0–2) 104 56
Advanced fibrosis (3–4) 39 26
1Weight is in US pounds.
2Likelihood ratio = 24.72, p= 4.361026. Il28B rs12979860 SNP genotypes were determined for 107 AA and 60 C.
doi:10.1371/journal.pone.0104202.t001
IFN Gene Signature and HepC Patient Response
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The expression of a subset of the IFN gene signature
correlates with the patient response to therapy
In the 130 liver samples subjected to Nanostring analysis, 43
were obtained from HCV-infected patients who responded to
IFN-ribavirin therapy (responders), 56 from HCV-infected
patients who did not respond to therapy (nonresponders), and
31 from patients who had an initial virological response to therapy,
but then relapsed during therapy and had high viral HCV titers
(relapsers). Of these 130 patient samples, 112 had their IL28B
genotype determined (Table 3). The liver tissue was obtained from
80 African-American (AA) and 50 Caucasian hepatitis C-infected
patients (Table 4). Consistent with the previous findings that
African Americans demonstrate a lower response rate to IFN than
Caucasians, in the African American group of patients 27.5%
were classified as responders, 57.5% as non-responders and 15%
as relapsers. In contrast, in the Caucasian group of patients 50%
were classified as responders, 22.1% as non-responders and 27.9%
as relapsers. Initial analysis of differences in gene expression
Table 2. Expression of the IFN Gene Signature.
Gene Minimum Maximum Mean Std Error Median
ANGPT2 b 1 132.8 7. 7 1.4 2.3
CASP4 c 54.4 214.6 102.9 2.8 95.4
CCL5 b 49.1 469.2 160.5 6.6 143.6
DDX58 b 60.7 450.9 200.8 7.3 189.7
DHX58 a 84.9 507.1 223.7 8.1 215.4
EIF2AK2 a 117.6 554.1 311.7 9.6 309.3
GADD45B d 56.6 584.2 158.5 6.9 144.6
GADD45G d 1 112.6 16.9 1.7 12.3
GBP1 b 94.8 482.9 266.2 7.38 260.4
HIF3A d 1 202.2 8.6 2.5 1
IFI16 a 43.3 280.1 132.5 4.5 125.6
IFI6 a 258.6 11402.8 5904.4 289.9 6385.7
IFIH1 b 51.6 316.4 158.4 5.9 157
IFNB1 b 1 274 5.8 2.5 1
IL6 b 1 79.2 6.9 1.4 1
IRF1 d 27.9 208.7 78.8 3.1 69.5
IRF2 a 95.2 422.7 188.8 4.4 184
IRF5 b 10.8 253.8 45.9 2.9 39
IRF7 b 107.5 1121 323.8 15.08 302.5
IRF9 b 293.3 1524.4 635.5 17.0 631
ISG20 b 23.8 395 111.8 6.0 97. 7
MAVS c 108 939.5 282.6 10.8 261.6
MX1 a 1 96.8 24.7 2.0 20.1
MYD88 d 107 378.6 217.2 4.8 219.3
OAS1 a 198.5 1660.4 905.5 35.7 932.2
PLSCR1 a 96.5 560 248.2 8.5 244.8
PML a 49.1 798.3 207.5 10.7 184.1
RARRES3 a 200 797.6 405.0 11.0 393.7
RSAD2 a 1.6 346.5 118.3 7.4 108.6
SOCS1 a 1 99.6 10.4 1.4 5.1
STAT1 b 347.8 3343.8 1492.0 53.2 1456.6
STAT2 a 413 1532.1 818.0 21.0 816.3
TAP1 a 28.1 253.8 86.8 3.2 84.6
TLR2 a 21.3 213.5 59.5 3.2 51.3
TLR3 a 4.2 193.3 45.9 2.3 43.1
TNFRSF10B c 33.7 194.8 77.5 2.7 72.8
TNFSF10 a 303.1 1929.8 898.1 29.7 857
VEGFC c 1 92.4 17.9 1.6 12.4
XAF1 d 101.9 988 403.9 15.6 421.5
Key: a,ISRE-driven ISGs, b ISRE-driven ISGs potentially regulated by NF-kB, c SIE-driven ISGs, and d SIE-driven ISGs potentially regulated by NF-kB.
doi:10.1371/journal.pone.0104202.t002
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between responders and non-responders (excluding relapsers)
revealed statistically significant differences (p,0.05) in the
expression of 16 out of the 39 genes examined, which included
CCL5, DDX58/RIG-I, DHX58/LGP2, EIF2AK2, IFI6, IFI16,
IFIH1/MDA5, IRF7, ISG20, MX1, OAS1, PLSCR1, RSAD2,
STAT1, TLR3 and XAF1 (Figure 1). Most interestingly, these
genes were expressed at higher levels in liver biopsies from patients
that did not respond to IFN-ribavirin therapy as compared to the
responders to therapy. The higher expression levels of ISGs prior
to therapy in nonresponders compared with responders was
consistent with several previous reports [27–30]. It is important to
note that there was no relationship found between the expression
of the IFNb gene in liver biopsies, and responsiveness to
exogenous IFN therapy. This finding is consistent with our
previous report that serum levels of type I IFNs in patients
chronically infected with HCV did not correlate with the response
to exogenous IFN therapy [22].
In addition we subjected the data collected on gene expression
from relapsers and compared it to the data from responders and
nonresponders. Although there was no statistical difference
between the various genes in nonresponders and relapsers, the
expression of CASP4, GADD45G and IFI16 was found to be
statistically different between the relapsers and the responders to
IFN-ribavirin therapy. As shown in Figure 2, while CASP4 and
IFI16 expression was higher in the group of relapsers, GADD45G
expression was found to be somewhat lower. In addition, we
compared the expression of the IFN gene signature according to
race and found no statistical differences according to race, i.e. AA
responders did not differ from Caucasian responders, etc.
Cellular functions of genes associated with IFN
responsiveness
To gain insights into the cellular functions of the genes that were
found associated with IFN responsiveness, we performed signaling
pathway analysis using the Ingenuity Pathway analysis (IPA)
software. As shown in Figure 3, 4 and 5, several critical antiviral
signaling pathways were overrepresented in the genes that are
associated with IFN responsiveness, For example TLR3, RIG-I/
DDX58, MDA5/IFIH1, PKR/EIF2AK2, OAS1, IRF7 and
RANTES/CCL5 are expressed at higher levels in nonresponders
and are components in the pattern recognition receptor (PRR)
pathway that is involved in the recognition of bacteria and viruses
(Figure 4). Of these, TLR3 is known to recognize dsRNA
intermediates produced during HCV RNA replication [31,32],
while RIG-I senses 59-triphosphate-bearing, genomic or antige-
nomic HCV RNAs [33]. Activation of either pathway in
hepatocytes leads to an IFN response that restricts HCV
replication. PKR has also been shown to recognize HCV RNA
[34], although it is uncertain whether PKR has an antiviral and/
or proviral effect [2]. OAS1 is a component of the OAS-RNase L
system that had been shown to detect and degrade HCV RNA in
HeLa cytoplasmic extracts [35]. In addition, RIG-I, LGP2,
MDA5, IRF7 and STAT1 are also expressed at higher levels in
nonresponders (Figure 5) and are components of the pathways
leading to IRF activation by cytosolic PRRs or signaling to ISG
induction downstream of the IFN receptors, which result in an
innate immune response against viruses and bacteria. Further-
more, genes with significantly higher expression in nonresponders
included two ISGs that possess anti-HCV activity in cell culture,
i.e. RSAD2/viperin and ISG20 [24,36].
Nucleotide polymorphism in the IL28B gene is highly
predictive of the response to IFN/ribavirin in HCV-
infected patients
AA in the present study had ,three-fold higher inheritance of
the homozygous TT genotype at the Il28B-associated rs12979860
SNP compared to homozygous CC (Table 3). In contrast, C had
,four-fold higher inheritance of CC compared to TT. These
results are consistent with the well-established racially associated
difference in inheritance at rs12979860 in chronic HCV infection
[11–14]. The inheritance of the CC versus TT or CT genotypes at
rs12979860 was highly correlated with (OR = 3.17, 95% CI 1.004
– 9.989, p=0.049) a sustained response of HCV-infected patients
to IFN-ribavirin therapy (responders). In addition, failure to
respond to therapy (nonresponders), or an initial virological
response to therapy but then relapsed with high viral HCV titers
(relapsers) was highly dependent upon rs12979860 genotype
(p=0.000972) and race (p=0.00861). Although rs12979860
genotype and other il28B-associated SNPs in linkage disequilib-
rium may be the most important correlates for racially associated
differences in response to IFN-ribavirin therapy for hepatitis C,
factors not associated with the il28B locus also contribute to
racially associated response differences.
The development of a predictive model for the patient
response to therapy based on the expression of IFN
signature genes, and nucleotide polymorphism in the
IL28B gene
Using logistic regression with cross validation, we found that the
best model contained RSAD2, IFI6, IFI16, STAT1, CCL5, and
XAF1. We show the results of the logistic regression models in
Table 5. We note that not all variables were statistically significant
in the final models. Although we used statistical significance to
help develop candidate models, we selected the final model based
Table 3. IL28 Genotype analysis (112/130 patients).
Genotype R NR Relapser AA CA
CT 21 (35%) 22 (37%) 17 (28%) 35 (58%) 25 (52%)
TT 4 (11%) 21 (60%) 10 (29%) 29 (83%) 6 (17%)
CC 10 (59%) 3 (18%) 4 (23%) 5 (29%) 12 (71%)
doi:10.1371/journal.pone.0104202.t003
Table 4. Patient Demographics.
Patient Response AA Caucasians
Responders 22 (17%) 25 (19%)
Nonresponders 46 (35%) 11 (9%)
Relapsers 12 (9%) 14 (11%)
doi:10.1371/journal.pone.0104202.t004
IFN Gene Signature and HepC Patient Response
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on its predictive potential in the 10-fold cross validation procedure.
Higher expression levels of RSAD2, IFI6, IFI16, and CCL5 were
associated with a reduced probability of patient response to IFN.
Lower expression of STAT1 and XAF1 were associated with
increased probability of response. Interestingly, race was not
strongly predictive of response when controlling for the effects of
these genes, indicating that we may have identified some of the
genetic factors that reduce response rates among African
Americans. Our model accurately predicted response for 79.2%
of individuals, with a specificity of 90% and sensitivity of 58% (See
Figure 6). Therefore, although the model rarely predicted
response when the true outcome was nonresponse/relapse (false
positives), it lacked sensitivity with several false negatives. Model-
based predictions were superior to race alone, which was not very
predictive of response with only 60% overall accuracy.
IL28B status was available in 112 out of the 130 patients whose
IFN-response gene signature was examined. In this subset of
patients, our expression-based model using RSAD2, IFI6, IFI16,
CCL5, XAF1, and STAT1 was 73.0% accurate. Although this
was lower than accuracy for the cohort as a whole, it still
performed better than other expression-based models. We found
that we could improve performance by including IL28B status.
Combining this with RSAD2, IFI6, IFI16, and CCL5 had 74.9%
accuracy. Importantly, this model had improved accuracy over a
model with IL28B and race alone (without expression data), which
had an accuracy of 67.8%.
Figure 1. Differential expression of an IFN-regulated signature geneset in responders versus nonresponders to therapy. Expression
of an IFN-regulated signature geneset was determined in RNA extracted from FFPE liver biopsies by nCounter analysis. Boxplots of genes found to be
statistically differentially expressed by nonparametric Mann-Whitney analysis (p,0.05).
doi:10.1371/journal.pone.0104202.g001
Figure 2. Differential expression of an IFN-regulated signature
geneset in relapsers versus responders to IFN-ribavirin therapy
to therapy. Expression of an IFN signature geneset was determined in
RNA extracted from FFPE liver biopsies by nCounter analysis. Boxplots
of genes found to be statistically differentially expressed by nonpara-
metric Mann-Whitney analysis (p,0.05).
doi:10.1371/journal.pone.0104202.g002
IFN Gene Signature and HepC Patient Response
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Discussion
Approximately 3% of the world’s population is infected with
HCV, and ,80% of HCV-infected individuals eventually become
chronically infected. While long-term persistence results predom-
inantly from evasion of the adaptive immune response to viral
infection, evasion of host innate immune response is believed to
contribute to establishing persistent HCV infection [6]. The IFN
system is a key player in the innate immune response against viral
infections, by inducing an antiviral state in the host against a
variety of viral pathogens. Moreover, HCV is highly sensitive to
treatment with type I and type III IFNs in vitro, and IFN remains
Figure 3. Signaling networks of genes that are associated with IFN responsiveness. The gene network was generated using Ingenuity
Pathway Analysis software.
doi:10.1371/journal.pone.0104202.g003
Figure 4. Genes in the pattern recognition receptor pathway are associated with IFN responsiveness. The gene network was generated
using Ingenuity Pathway Analysis software. Genes upregulated in nonresponders (shown in Figure 1) were highlighted. As expected, several antiviral
signaling pathways were overrepresented in these genes.
doi:10.1371/journal.pone.0104202.g004
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a mainstay of treatment of HCV infected patients [37]. However,
precisely why the current IFNa-based therapy is only effective in a
proportion of treated patients remains largely a mystery, and this
has been an area of intensive investigation. In the present study we
compared expression of an IFN-response geneset in FFPE derived
from liver biopsies from patients enrolled in an IFN-ribavirin trial
conduced at UTHSC, which were taken before therapy was
initiated. Our goal was to establish an IFN-response gene
signature that can be used to predict IFN-responsiveness in
hepatitis C patients.
The IFN-response signature geneset was based on our own
microarray studies on IFN-induced genes in human and mouse
cell lines, a database of IFN-stimulated genes from a variety of
cells, and regulatory elements of gene promoter regions. Our
strategy was to focus on genes that may play an important role in
the antiviral innate immune response, and that were induced by
various IFN activated signaling pathways. Thus genes such as Mx1
and PKR/EIF2AK2 contain an ISRE (IFN-stimulated response
element), and are induced by the classical IFN-activated signaling
that involved JAK1 and TYK2 activation and STAT1 and
STAT2 transcription factors [38]. However ISGs such as RIG-I/
DDX58 and MDA5/IFIH1 may be induced through an NF-kB-
dependent pathway as well [16]. In addition, a number of ISGs
such as VISA/MAVS and Casp4 do not contain an ISRE but
rather an SIE (c-sis-inducible element) and appear to be regulated
by STAT1 and STAT3 homodimers and heterodimers [39]. In
addition, some SIE-containing ISGs such as IRF1 and MYD88
may also be regulated through an NF-kB-dependent pathway
[18]. All 39 members of the IFN-regulated signature gene set were
induced upon IFNa treatment of Huh7 hepatoma cells (data not
shown).
Figure 5. Genes in IRF activation by cytosolic pattern recognition receptors are associated with IFN responsiveness. The gene
network was generated using Ingenuity Pathway Analysis software. Genes upregulated in nonresponders (shown in Figure 1 and 2) were highlighted.
doi:10.1371/journal.pone.0104202.g005
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We found that nearly all 39 of the IFN-response signature genes
were expressed in liver biopsies from chronically HCV-infected
patients enrolled in the clinical trial of IFN-ribavirin at UTHSC.
Previous studies using microarrays to determine global gene
expression of liver biopsies from chronically HCV-infected
patients and from experimentally HCV-infected chimpanzees
show elevated ISG expression [23–26]. In addition, there was a
great deal of heterogeneity in the expression level of the signature
genes in the different patients. For example, genes that were
expressed at relatively low levels such as IFNb, IL6, TNFRSF10B,
VEGFC and ANGPT2 were expressed only in a subset of patient
samples. In contrast, genes that were expressed at relatively high
levels such as TNFSF10 (TRAIL), OAS1, RANTES (CCL5) and
IRF9 were detected in all liver biopsies. It is of particular interest
that only a small fraction of liver biopsies (,10%) from patients
chronically infected with HCV expressed the IFNb gene. While
this seems to conflict with our previous finding that ,50% of the
serum samples from a smaller patient population in the clinical
Table 5. Logistic regression modeling of patient data.
Expression-based model (N=130)
Gene OR* 95% CI
RSAD2 0.863 0.755 0.986
IFI6 0.997 0.994 0.999
IFI16 0.867 0.758 0.992
STAT1 1.014 1.000 1.029
CCL5 0.927 0.857 1.002
XAF1 1.053 1.008 1.100
Expression and IL28 model (N=115)
Gene OR* 95% CI
RSAD2 0.947 0.850 1.056
IFI6 1.000 0.997 1.002
IFI16 0.978 0.869 1.101
CCL5 0.910 0.833 0.993
IL28B 2.988 1.271 7.024
*OR for gene expression is for a change of 10 units.
doi:10.1371/journal.pone.0104202.t005
Figure 6. The distribution of predicted probability of therapeutic response (with relapsers included). We found that those who actually
responded to IFN-ribavirin treatment had higher predicted probabilities of response in the model.
doi:10.1371/journal.pone.0104202.g006
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trial of IFN-ribavirin had detectable levels of type I IFN [22], it is
conceivable that most of the circulating levels of type I IFN derive
from extrahepatic sources such as the plasmacytoid dendritic cells.
Consistent with our data, two recent studies have shown that type
III IFNs rather than type I IFNs are induced in the liver of
experimentally HCV-infected chimpanzees and that the intrahe-
patic level of type III IFNs correlates with that of ISG expression
[40,41]. Our IFN-response geneset did not contain type III IFN
genes, since when this study was initiated and the geneset was
constructed a role for IL29/IL28B in hepatic innate immunity to
HCV infection was not recognized. Nevertheless, it is worth noting
that intrahepatic type III IFN level was not found to associate with
the outcome of acute HCV infection [40], nor was it related to
response to IFN therapy in patients with chronic hepatitis C [42].
Another important finding from these studies is that expression
of a subset of these genes in liver biopsies inversely correlated with
the responsiveness to IFN-ribavirin therapy, i.e. higher expression
was observed in nonresponders as compared to responders.
Although this finding is counterintuitive, as one would expect an
active IFN system would help eliminate the virus during therapy, it
is supported by a number of studies, which have shown that
patients with a high ISG expression prior to the initiation of IFN
therapy seem to respond poorly to IFN therapy [27–30].
Additional support is lent from a study showing that the expression
of intrahepatic ISGs was already maximally induced in chimpan-
zees chronically infected with HCV. Consequently, when exoge-
nous IFN was administered, there was no further ISG upregula-
tion [43]. Although the underlying mechanism remains elusive,
nonresponder hepatitis C patients tend to have pre-activated Jak-
STAT pathway prior to therapy, which may connect to IFN
refractoriness [27].
However, it is important to note that in our study only a subset
of the IFN-regulated genes examined were expressed at a
statistically significant higher level in patients that were nonre-
sponsive to IFN therapy. Of particular interest, some of these
overexpressed genes were either involved in viral sensing (TLR3,
RIG-I/DDX58, DHX58/LGP2, MDA5) or effector functions of
IFNs (ISG20, RSAD2, PKR, etc.). Both TLR3 and RIG-I can
sense HCV RNA (although they recognize different viral ligand
forms) early after infection and initiate signaling pathways
culminating in the induction of an IFN response that curtails
HCV replication [32,33]. However, HCV has evolved to disarm
both mechanisms by NS3/4A-mediated cleavage of the essential
adaptor proteins, TRIF (Toll/interleukin receptor domain-con-
taining adapter-inducing interferon), and MAVS, once the
infection is established in hepatocytes [44–46]. Among the ISG
effectors, ISG20 and RSAD2 have been shown to inhibit HCV
replication, while controversial results have been reported for
PKR [2]. There are several possibilities that may explain why
induction of the endogenous anti-viral ISGs prior to IFN therapy
fails to contain HCV infection [47]. The anti-HCV ISGs may only
be transcriptionally upregulated in uninfected surrounding cells
but not in HCV-infected hepatocytes. Alternatively, ISG tran-
scripts may be made in both infected and uninfected cells but ISG
proteins are only made in uninfected cells because of PKR
activation in infected cells [48]. Third, some HCV proteins may
inhibit the effector functions of the antiviral ISGs. Regardless of
the infection/treatment outcome, the induction of a subset of IFN-
regulated signature genes we identified in treatment-naı¨ve patient
liver underscores the important roles these genes/pathways may
play in host attempts to control HCV infection in the liver.
In addition, we found CCL5/RANTES to be over-expressed in
both nonresponders and relapsers to IFN therapy. CCL5 is a
chemokine produced by monocyte/macrophage subsets in the
liver, which contributes to recruiting T cells and other leukocytes
to the infection site and also to the progression and resolution of
liver fibrosis [49]. A recent study from our group suggests that
infected hepatocytes represent a cellular source for CCL5
production at early phase of HCV infection, through TLR3-
mediated sensing of HCV dsRNA intermediates and subsequent
activation of NF-kB, a transcription factor pivotal for RANTES
synthesis [31]. CCL5 is associated with a Th1 lymphocyte-related
cytokine/chemokine profile and HCV clearance [50]. However,
CCL5 may also shape the IFN response in the liver by altering the
infiltration and activation of hepatic stellate cells, which maintains
chronic HCV infection in the liver in part by inhibiting liver
fibrosis [51]. Exactly how pre-activated intrahepatic RANTES
expression affects IFN responsiveness will require further study.
Our study also presents a predictive model for IFN responsive-
ness based on a small number of signature genes. Although
variants of the IL28B/IFNl3 gene have recently been found to be
highly predictive of the response to IFN/ribavirin in HCV-
infected patients [11–15], there has been a paucity of mechanistic
insights. Clearly, intrahepatic type III IFN levels of hepatitis C
patients are not affected by IL28B polymorphism [42,52], nor is it
the case in primary hepatocyte cultures infected by HCV in vitro
[40,53]. Thus, the underlying mechanism for differential response
in HCV-infected patients remains largely unknown. In our study
we show that the expression of RSAD2, IFI6, IFI16, STAT1,
CCL5, and XAF1 was highly predictive of the eventual IFN
responsiveness to IFN/ribavirin therapy. Future studies will
elucidate why lower expression of STAT1 and XAF1 were
predictive of IFN responsiveness while expression of RSAD2, IFI6,
IFI16, and CCL5 were associated with a poorer response to
therapy. The model must also be validated with external data, and
though our model had high specificity, further refinement is
needed to improve model sensitivity.
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